Dendritic Cell Vaccine

BIOLOGICAL18 trials

Sponsors

Ehime University Hospital, Dartmouth-Hitchcock Medical Center, Hospital Clinic of Barcelona, University of Maryland, Baltimore, Cedars-Sinai Medical Center

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAdult T-Cell Leukemia/LymphomaAnaplastic AstrocytomaBrain CancerBrain TumorChronic InfectionColorectal Neoplasms

Phase 1

Dendritic Cell Vaccine in HIV-1 Infection

CompletedNCT00402142

Hospital Clinic of BarcelonaHIV Infections

Start: 2006-11-30End: 2011-12-31Updated: 2014-02-26

Dendritic Cell Vaccine in HIV-1 Infection

CompletedNCT00402142

Hospital Clinic of BarcelonaHIV Infections

Start: 2006-11-30End: 2011-12-31Updated: 2014-02-26

Dendritic Cell Vaccine for Head and Neck Cancer

WithdrawnNCT00492947

University of Maryland, BaltimoreSquamous Cell Carcinoma of Head and Neck

Start: 2007-06-30End: 2012-06-30Updated: 2021-04-30

Surgical Resection With Gliadel Wafer Followed by Dendritic Cells Vaccination for Malignant Glioma Patients

CompletedNCT00576446

Cedars-Sinai Medical CenterMalignant Glioma

Start: 2007-04-30End: 2012-05-31Updated: 2013-02-20

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

CompletedNCT00700167

Memorial Sloan Kettering Cancer CenterMelanoma

Start: 2001-09-30End: 2011-04-30Updated: 2011-04-20

Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)

CompletedNCT00796770

Baylor Research InstituteHIV

Start: 2008-11-30End: 2011-09-30Updated: 2017-06-12

Vaccine Therapy in Curative Resected Prostate Cancer Patients

Oslo University HospitalProstate Cancer

Start: 2010-09-30End: 2025-09-30Target: 30Updated: 2022-09-27

Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma

CompletedNCT01808820

Macarena De La Fuente, MDAnaplastic Astrocytoma, Glioblastoma Multiforme, High Grade Glioma +1

Start: 2013-08-21End: 2022-07-16Updated: 2022-07-20

Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors

TerminatedNCT01902771

Edward ZigaBrain Cancer, Brain Tumor, Glioblastoma Multiforme +2

Start: 2013-09-03End: 2017-01-26Updated: 2017-03-10

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

Karolinska University HospitalMelanoma

Start: 2013-10-31End: 2025-12-31Target: 20Updated: 2022-10-04

Safety Trial of STING-dependent Activators and Stimulated Dendritic Cells for Aggressive Relapsed/Refractory Leukemias

WithdrawnNCT05321940

Juan C. Ramos, MDAcute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Adult T-Cell Leukemia/Lymphoma +2

Start: 2023-11-30End: 2026-11-30Updated: 2023-12-04

Neoantigen Derived DCs as Cancer Treatment

RecruitingNCT05767684

National Health Research Institutes, TaiwanRefractory Tumor, Solid Tumor

Start: 2023-06-01End: 2026-03-30Target: 12Updated: 2023-08-25

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV)

RecruitingNCT05809752

H. Lee Moffitt Cancer Center and Research InstituteHER2-positive Breast Cancer, Leptomeningeal Disease, Triple Negative Breast Cancer

Start: 2023-08-22End: 2026-03-01Target: 18Updated: 2026-04-01

Phase 2

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

CompletedNCT00323115

Dartmouth-Hitchcock Medical CenterGlioblastoma Multiforme

Start: 2006-05-31End: 2013-07-31Updated: 2018-10-10

Randomized Trial With Dendritic Cells in Patients With Metastatic Colorectal Cancer

CompletedNCT01413295

Fundacion Clinic per a la Recerca BiomédicaColorectal Neoplasms

Start: 2011-08-31End: 2014-09-30Updated: 2014-11-04

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not yet recruitingNCT06805656

Federal University of São PauloHiv, HIV I Infection

Start: 2025-09-01End: 2027-12-31Target: 70Updated: 2025-08-11

Phase 3

Clinical Trial Assessing the Efficacy and Safety of Dendritic Cell-Based Immunotherapy for Glioblastoma

Not yet recruitingNCT06749925

University of Sao Paulo General HospitalGlioblastoma

Start: 2026-01-31End: 2029-01-31Target: 186Updated: 2025-04-01

Unknown Phase

Examination of the usefulness using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for postoperative therapy of oral malignant tumor.

RecruitingJPRN-UMIN000003545

Ehime University Hospitaloral malignant cancer

Start: 2010-04-01Target: 50Updated: 2025-07-18

Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure

CompletedNCT02961829

Federal University of São PauloChronic Infection, HIV

Start: 2015-07-31End: 2020-03-31Updated: 2020-07-28

Related Papers

Abstract PD13-07: A transcriptomic analysis of a first in human phase I trial of intrathecal dendritic cells (cDC1s) in patients with leptomeningeal disease (LMD) shows development of an adaptive immune response and very long survival in LMD

Clinical Cancer Research2026-02-17

TIP-24. A first-in-human trial of intrathecal cDC1 therapy for breast cancer leptomeningeal disease induces adaptive immunity with transcriptomic evidence of immune awakening in the CSF

Neuro-Oncology2025-11-01

OS06.3.A A FIRST IN HUMAN PHASE I TRIAL OF INTRATHECAL DENDRITIC CELLS PRIMED AGAINST HER2/HER3 IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM TRIPLE-NEGATIVE OR HER2+ BREAST CANCER SHOW DEVELOPMENT OF ADAPTIVE IMMUNE RESPONSES

Neuro-Oncology2025-10-01

BSLD-02 A FIRST IN HUMAN PHASE I TRIAL OF INTRATHECAL DENDRITIC CELLS PRIMED AGAINST HER2/HER3 IN PATIENTS WITH LEPTOMENINGEAL DISEASE FROM TRIPLE-NEGATIVE OR HER2+ BREAST CANCER SHOW DEVELOPMENT OF ADAPTIVE IMMUNE RESPONSES

Neuro-Oncology Advances2025-08-01

Investigation of cell therapies: a role for TIL and/or DC vaccines?

South East European Journal of Immunology2025-03-25

KS05.7.A INTRATHECAL DELIVERY OF PEPTIDE-PULSED TYPE 1 CONVENTIONAL DENDRITIC CELL VACCINE IS HIGHLY EFFICACIOUS FOR THE TREATMENT OF BREAST CANCER-ASSOCIATED LEPTOMENINGEAL DISEASE

Neuro-Oncology2024-10-01

BSLM-07 A FIRST IN HUMAN PHASE 1 TRIAL OF DOSE ESCALATING INTRATHECAL (IT) DENDRITIC CELLS (CDC1S) PRIMED AGAINST HER2/HER3 IN PATIENTS (PTS) WITH LEPTOMENINGEAL DISEASE (LMD) FROM TRIPLE NEGATIVE (TNBC) OR HER2+ BREAST CANCER (BC)

Neuro-Oncology Advances2024-08-011 citations

BSLM-04 INTRATHECAL DELIVERY OF PEPTIDE-PULSED TYPE 1 CONVENTIONAL DENDRITIC CELL VACCINE IS HIGHLY EFFICACIOUS FOR THE TREATMENT OF BREAST CANCER-ASSOCIATED LEPTOMENINGEAL DISEASE IN PRECLINICAL MODELS

Neuro-Oncology Advances2024-08-01

A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).

Journal of Clinical Oncology2024-06-011 citations

Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.

Journal of Clinical Oncology2024-06-01

Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.

2022-01-127 citations

Biochemical relapse in very high-risk prostate cancer after radical prostatectomy and DC-vaccine loaded with tumor RNA, hTERT, and survivin.

Journal of Clinical Oncology2020-02-192 citations

Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination

OncoImmunology2020-01-0147 citations

Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial.

2019-08-0535 citations

HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.

2015-06-2427 citations

Phase II randomized trial of autologous tumor lysate dendritic cell vaccine (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced colorectal cancer patients.

Journal of Clinical Oncology2015-05-208 citations

A phase I study of adoptive T-cell therapy with or without dendritic cell vaccination in patients with metastatic melanoma.

Journal of Clinical Oncology2014-05-201 citations

Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccines.

2011-06-149 citations

Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.

2011-02-2559 citations

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine.

2010-11-1833 citations